[144] Agios Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Agios Pharmaceuticals, Inc. (AGIO) has filed a Form 144 with the U.S. Securities and Exchange Commission disclosing a proposed insider sale under Rule 144.

• Shares to be sold: 1,761 shares of common stock
• Aggregate market value: $60,596
• Approximate sale date: 06/24/2025
• Broker: Morgan Stanley Smith Barney LLC, New York, NY
• Shares outstanding: 57,915,199
• Source of shares: Vesting of restricted stock on 06/24/2025
• Exchange: Nasdaq

The proposed sale represents roughly 0.003% of the company’s outstanding shares, indicating a de-minimis transaction that is unlikely to have a material effect on the company’s capital structure or market liquidity. No prior sales were reported in the past three months, and the filer attests to possessing no undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine, very small insider sale; negligible impact on AGIO shares.

The Form 144 discloses an intention to sell 1,761 shares—about 0.003% of Agios’ 57.9 million outstanding shares—valued at $60.6 thousand. The shares stem from a scheduled restricted-stock vesting, suggesting normal liquidity management rather than a strategic shift or negative signal. Given the immaterial size, the filing should not meaningfully affect the float, ownership concentration, or investor sentiment. Such routine disclosures are common for executives managing tax liabilities or diversification. Unless accompanied by larger insider sales or adverse operational news, the market impact is expected to be neutral.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1761	60596.00	57915199	06/24/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/24/2025	Vesting of Restricted Stock	Issuer			1761	06/24/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many AGIO shares are being sold under this Form 144?

The filing covers 1,761 shares of Agios Pharmaceuticals common stock.

What is the total market value of the proposed AGIO insider sale?

The aggregate market value is $60,596.

When is the approximate sale date for the AGIO shares?

The filer plans to sell on or around 06/24/2025.

What percentage of Agios Pharmaceuticals’ outstanding shares does this sale represent?

Approximately 0.003% of the 57,915,199 shares outstanding.

Which broker is handling the AGIO share sale?

The sale will be executed through Morgan Stanley Smith Barney LLC.